Results 51 to 60 of about 25,878 (248)

In Vivo Electrochemical Monitoring of Safinamide Pharmacokinetics in the Brain Explores Its Correlation With Vision‐Related Neuronal Activity

Advanced Science, EarlyView.
An electrochemical platform based on differential pulse amperometry enables real‐time, selective tracking of safinamide pharmacokinetics in the living brain with high spatiotemporal resolution. When integrated with electrophysiology, this approach reveals that drug‐induced suppression of vision‐related neuronal activity provides mechanistic insight ...
Xiaoke Nan, Chuqi Li, Qianhe Dai, Junlan Zhou, Lijiao Cao, Yuying Liu, Jinger Chen, Meiping Xiong, Yuhang Jiang, Xianchan Li   +9 more
wiley   +1 more source

MAO inhibitors for treatment-resistant depression: Bringing an updated perspective on pioneering drugs

Pharmacological Research
In the 1950s, monoamine oxidase inhibitors transformed the pharmacological treatment of mental disorders as the first class of antidepressant drugs.
Larissa Junkes, Laiana A. Quagliato, Jose C. Appolinario, Richard I. Shader, Antonio E. Nardi   +4 more
doaj   +1 more source

Circular Economy‐Driven Cs/Sg/MGNPs/AC Composite for Efficient Methylene Blue Removal and Subsequent Valorization as a Urea Oxidation Electrocatalyst

Journal of Applied Polymer Science, EarlyView.
This image is a graphical abstract for outlining the synthesis, characterization, and application of a novel composite material designed to remove toxic pollutants (specifically Methylene Blue dye; MB) from water, and its subsequent use in electrochemical applications.
Rehab Mahmoud, Lina M. Alneghery, Ahmed Abdelazim Khalifa, Marwa H. Shemy, Ahmed A. Allam, Saber A. A. Elsuccary, Samar M. Mahgoub   +6 more
wiley   +1 more source

Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells

, 2007
Monoamine oxidases (MAOs) are mitochondrial enzymes which control the levels of neurotransmitters in the brain and dietary amines in peripheral tissues via oxidative deamination. MAO has also been implicated in cell signalling. In this study, we describe
Ufer, C, Kuhn, H, Billett, EE, Fitzgerald, JC, De Girolamo, LA, Hartmut Kuhn, Luigi A. De Girolamo, Christoph Ufer, E. Ellen Billett, Julia C. Fitzgerald   +9 more
core   +1 more source

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

BMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim, Hak Yong Kim, Ja Hoon Koo, Gi Doo Cha, Dae‐Hyeong Kim, Hye Jin Kim   +5 more
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Inhibition of  monoamine oxidase by 8-benzyloxycaffeine analogues

, 2010
Based on recent reports that several (E)-8-styrylcaffeinyl analogues are potent reversible inhibitors of monoamine oxidase B (MAO-B), a series of 8-benzyloxycaffeinyl analogues were synthesized and evaluated as inhibitors of baboon liver MAO-B and ...
Petzer, Jacobus P., Castagnoli, Neal, Strydom, Belinda, Bergh, Jacobus J., Malan, Sarel F.   +4 more
core   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source

Neuroprotection by dopamine agonists

, 1994
Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents.
Rausch, W. D., Naumann, M., Riederer, P., Oestreicher, E., Lange, Klaus W., Gsell, W.   +5 more
core   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source